CSBio CSBio

X
[{"orgOrder":0,"company":"Alebund Pharmaceuticals","sponsor":"Quan Capital","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alebund Pharmaceuticals Raises $60 million in Series B Financing Round","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Alebund Pharmaceuticals"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCity Announces Initiation of a Phase 2 Trial for SC0062, a Promising ETA Receptor Antagonist for Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"BioCity Biopharma"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCity Announces Enrollment Completion of the IgA Nephropathy (IgAN) Cohort in the Randomized, Placebo-controlled Phase II Clinical Trial of the ETA Receptor Antagonist SC0062","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"BioCity Biopharma"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            SC0062 is one of the most unique, oral endothelin A (ETA)-receptor selective antagonist, small molecule drug. It is being evaluated for the treatment of IgA Nephropathy.

            Lead Product(s): SC0062

            Therapeutic Area: Nephrology Product Name: SC0062

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 26, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            SC0062 is designed with high selectivity for ETA receptors antagonists, which is investigated for the treatment of chronic kidney disease with albuminuria.

            Lead Product(s): SC0062

            Therapeutic Area: Nephrology Product Name: SC0062

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 21, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Alebund Pharmaceuticals lead product, AP-301, is a best-in-class potential in the treatment of hyperphosphatemia.

            Lead Product(s): Solnatide

            Therapeutic Area: Nephrology Product Name: AP-301

            Highest Development Status: Phase II Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Quan Capital

            Deal Size: $60.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing May 09, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY